Unlock new possibilities in mRNA research with GenScript's patented GenCap™ technologies. Our innovations are designed to elevate your mRNA research capabilities with enhanced stability, efficiency, and targeting. Additionally, we continue to introduce cutting-edge technologies, including Cap2, circular RNA, and self-amplifying RNA platforms. Partner with GenScript to drive your RNA projects forward.
Co-transcriptional Capping Method
Selection of UTRs
For improving RNA expression at specific organs
Optimized PolyA Vector
For stable expression of polyA containing plasmid
GenScript patented Capping Technology has a new co-transcriptional capping method to make mRNA, yielding high capping efficiency and mRNA with more homogenous 5’end .
The final cap1 structure after GenScript’s co-transcriptional capping technology
GenCap™ Technology Benefit
The GenCap™ optimized IVT method ensures the production of high-integrity mRNA, resulting in enhanced mRNA expression.
Fluc mRNA Purity mRNA integrity by Bioanalyzer
Fluc mRNA Expression in A549 Cells
Optimizing UTR Selection for Tissue-Specific Enhanced mRNA Expression
The GenCap™ optimized IVT method ensures the production of high-integrity mRNA, significantly reducing its immunogenicity.
The Optimized PolyA vector technology facilitates the stable incorporation of polyA sequences into plasmids. The uniformity of the polyA tail is crucial, as it significantly influences mRNA expression efficiency.
Poly(A) Tail integrity Compared with other vendors
The length of the polyA tail significantly impacts mRNA
expression
efficiency in cells, with tails longer than 80 adenines (80As) typically being
preferred.
Poly(A) Length Impacts Expression
Cap 2 Technology
CircRNA Platform
saRNA Platform
GenScript developed novel Cap2 technology that marks a groundbreaking advancement in the field of mRNA research, enhancing the stability and translation efficiency of mRNA molecules.
Cap2 RNA was reported to have better expression than Cap1 RNA in stressed condition*. By improving the efficacy and durability of mRNA constructs, Cap 2 technology paves the way for more effective treatments in the development of mRNA-based therapeutics and vaccines.
*Drazkowska K, Tomecki R, et al. Nucleic acid Research, 2022 Nucleic Acids Res. 2022 Sep 9; 50(16): 9051–9071
Cap 2 Structure
mRNA Expression Without Stress
mRNA Expression Under Stress Conditions
Cap0: positive sense RNA viruses such as alphaviridae-like virus RNA mainly uses cap0 mechanism.
Cap1: crucial for mammalian cells to distinguish self or non-self mRNAs during viral infection
Cap2: Cap2 impacts the protein production in a cell-specific manner and contributes to RNA immune evasion
Yasuhiro Furuichi, Proc Jap Acad, Ser, B91(2005), V91: 394 Karolina Drazkowaska, Nucleic Acid Research 2022, Aug 26
